Jane Street’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-7,949
Closed -$377K 11002
2025
Q3
$377K Buy
+7,949
New +$385K ﹤0.01% 8456
2025
Q2
Sell
-182,457
Closed -$8.29M 9523
2025
Q1
$7.39M Sell
182,457
-42,562
-19% -$1.8M ﹤0.01% 2378
2024
Q4
$6.26M Buy
225,019
+7,455
+3% +$226K ﹤0.01% 2380
2024
Q3
$6.24M Sell
217,564
-39,970
-16% -$1.04M ﹤0.01% 2506
2024
Q2
$6.04M Buy
257,534
+7,459
+3% +$160K ﹤0.01% 2699
2024
Q1
$6.32M Sell
250,075
-5,474
-2% -$131K ﹤0.01% 2312
2023
Q4
$5.97M Buy
255,549
+79,513
+45% +$1.57M ﹤0.01% 2608
2023
Q3
$8.9M Sell
176,036
-88,390
-33% -$4.12M ﹤0.01% 1902
2023
Q2
$12.3M Buy
264,426
+203,790
+336% +$9.34M ﹤0.01% 1693
2023
Q1
$2.32M Buy
60,636
+26,496
+78% +$1.18M ﹤0.01% 3562
2022
Q4
$1.87M Buy
34,140
+26,236
+332% +$1.12M ﹤0.01% 3965
2022
Q3
$269K Sell
7,904
-2,926
-27% -$44.8K ﹤0.01% 7751
2022
Q2
$102K Sell
10,830
-15,822
-59% -$165K ﹤0.01% 8625
2022
Q1
$378K Sell
26,652
-3,377
-11% -$59.1K ﹤0.01% 7984
2021
Q4
$635K Buy
30,029
+5,996
+25% +$133K ﹤0.01% 6810
2021
Q3
$538K Buy
24,033
+15,353
+177% +$348K ﹤0.01% 7146
2021
Q2
$216K Sell
8,680
-2,304
-21% -$64.7K ﹤0.01% 8687
2021
Q1
$319K Buy
+10,984
New +$332K ﹤0.01% 7603

Other funds holding AKRO

Jane Street's AKRO Position: Q4 2025 in Review

Jane Street sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 7,949 shares — an estimated $377K sold.

Jane Street first reported a position in AKRO in Q1 2021 and held it in 18 quarters. The position peaked at $12.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Jane Street reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 7,949 Akero Therapeutics shares in Q4 2025, an estimated $377K.
  • Jane Street first reported a position in Akero Therapeutics in Q1 2021 and held it in 18 quarters.
  • Jane Street's Akero Therapeutics position peaked at $12.3M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.